Read + Share
Amedeo Smart
Independent Medical Education
Gelbenegger G, Jaeger U, Fillitz M, D'Sa S, et al. Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial. Br J Haematol 2022;198:e59-e62.PMID: 35655238
Email
LinkedIn
Facebook
Twitter
Privacy Policy